ITRI's Intelligent Radio Frequency Ablation (iRFA) system was transferred to Compal Electronics, becoming the first case in Taiwan of an ICT company entering the therapeutic medical device segment. In September this year, the system was successfully covered by the National Health Insurance and received US and Taiwan marketing approval, and there have already been five successful cases in domestic hospitals, with good recovery after treatment.

Radiofrequency ablation (RFA) is a safe and minimally invasive treatment and is the most widely used tumour ablation technique in the world. Using the guided image, a very small electrode needle is located and inserted into the area of the tumour, and the needle emits radiofrequency (RF) waves which heat the tissue as a result of ionic excitation and disruption, causing the tumour in the treatment area to be cauterised and necrotic as a result of the increase in temperature, commonly referred to as 'electrocautery'.

Compal's AblatePal radiofrequency ablation system uses high-frequency electrical energy to destroy cells inside tissues, causing them to lose their ability to grow, in order to achieve the effect of treating diseases. The radiofrequency ablation system can be used not only for cancer treatments, but also for other conditions such as heart diseases and tumours.

Compal and NTUH held a ribbon-cutting ceremony to unveil the "NTU Compal Radiofrequency Ablation Training Centre" this morning.